The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive ...

What you need to know ### BMJ Learning To obtain accredited continuous professional development points, subscribers to BMJ Learning can complete the full module at The module contains seven ...

While children under five, particularly those under two, are the most vulnerable, pneumococcal diseases also affect adults. The most common symptoms include cough, chills and fever.

polysaccharide-based jab Pneumovax 23. Sanofi's new challenger is billed as a "next-generation" pneumococcal conjugate vaccine that, according to the company, is the first candidate with more than ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended four novel medicines for approval at its January 2025 meeting, as well as some biosimilars.

The pneumococcal conjugate vaccine (PCV13) should be administered first, followed by the pneumococcal polysaccharide vaccine (PPSV23) after one year for at-risk individuals or eight weeks for those at ...

For prevention of IPD, the National Advisory Committee on Immunization (NACI) has recommended the 23-valent polysaccharide pneumococcal vaccine, PNEU-P-23, for adults 65 years of age and older and ...

Merck already sells an older pneumococcal vaccine called Pneumovax 23, which protects against 23 strains but is a polysaccharide based shot, so doesn't stimulate as strong an immune response as ...